Want to see IN:MARKSANS full AI Analyst Report?
Top Page
Marksans Pharma Limited
(MARKSANS)
Select Model
Select Model
Rating:70Outperform
Price Target:
₹326.00
▲(79.07% Upside)
Action:Upgraded
Date:08/17/26
The score is driven primarily by strong financial quality (steady growth, solid profitability, and low leverage), partially offset by margin compression and historically uneven cash conversion. Technically, the uptrend is strong but appears overextended, and valuation is relatively expensive with a low dividend yield.
Positive Factors
Steady Revenue Growth
Sustained revenue expansion indicates continuing demand for Marksans Pharma’s generic products across its markets. Although FY2026 growth moderated, the multi-year pattern supports an established commercial platform and provides a durable base for future earnings growth.
Negative Factors
Gross Margin Compression
The sharp FY2026 gross-margin decline signals pressure on the economics of products sold, whether from mix or costs as indicated in the financial analysis. If persistent, this could reduce operating leverage and limit how much revenue growth translates into profit.
Read all positive and negative factors
Positive Factors
Negative Factors
Steady Revenue Growth
Sustained revenue expansion indicates continuing demand for Marksans Pharma’s generic products across its markets. Although FY2026 growth moderated, the multi-year pattern supports an established commercial platform and provides a durable base for future earnings growth.
Read all positive factors
Marksans Pharma Limited (MARKSANS) vs. iShares MSCI India ETF (INDA)
Market Cap
₹138.96B
Dividend Yield0.29%
Average Volume (3M)100.25K
Price to Earnings (P/E)26.8
Beta (1Y)1.22
Revenue Growth19.59%
EPS Growth47.58%
CountryIN
Employees1,685
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)11.41
Shares Outstanding453,163,760
10 Day Avg. Volume66,287
30 Day Avg. Volume100,247
Financial Highlights & Ratios
PEG Ratio1.74
Price to Book (P/B)2.35
Price to Sales (P/S)2.41
P/FCF Ratio20.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)12.55
Revenue Forecast (FY)₹35.68B
Marksans Pharma Limited Business Overview & Revenue Model
Company Description
Marksans Pharma Limited, along with its subsidiaries, operates internationally, engaging in the full spectrum of generic pharmaceutical formulation activities, from research and development and manufacturing to marketing, distribution, and sales. ...
Marksans Pharma Limited Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
86
Very Positive
Cash Flow
70
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 31.72B | 29.51B | 26.23B | 21.77B | 18.52B | 14.80B |
| Gross Profit | 14.06B | 11.57B | 14.79B | 11.03B | 9.31B | 7.32B |
| EBITDA | 7.55B | 6.03B | 5.29B | 5.09B | 3.99B | 3.01B |
| Net Income | 5.17B | 4.18B | 3.81B | 3.14B | 2.66B | 1.85B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 38.61B | 32.40B | 26.81B | 21.90B | 16.40B |
| Cash, Cash Equivalents and Short-Term Investments | 9.91B | 9.90B | 7.05B | 7.00B | 7.19B | 3.47B |
| Total Debt | 0.00 | 3.43B | 3.22B | 2.44B | 1.23B | 1.11B |
| Total Liabilities | -30.53B | 8.08B | 7.50B | 5.95B | 4.25B | 4.17B |
| Stockholders Equity | 30.53B | 30.23B | 24.67B | 20.65B | 17.45B | 12.02B |
Cash Flow | ||||||
| Free Cash Flow | 19.97M | 3.51B | 337.45M | 215.69M | 1.84B | 529.27M |
| Operating Cash Flow | 751.86M | 4.82B | 2.07B | 2.30B | 2.37B | 992.57M |
| Investing Cash Flow | -364.77M | -2.75B | -490.09M | -1.41B | -2.59B | -416.86M |
| Financing Cash Flow | -528.77M | -681.43M | -651.46M | -687.27M | 1.98B | 795.11M |
Marksans Pharma Limited Technical Analysis
Positive
182.05
Price Trends
320.92
Negative
294.11
Positive
239.45
Positive
Market Momentum
-4.84
Negative
47.47
Neutral
74.81
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:MARKSANS, the sentiment is Positive. The current price of 182.05 is below the 20-day moving average (MA) of 309.74, below the 50-day MA of 320.92, and below the 200-day MA of 239.45, indicating a neutral trend. The MACD of -4.84 indicates Negative momentum. The RSI at 47.47 is Neutral, neither overbought nor oversold. The STOCH value of 74.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:MARKSANS.
Marksans Pharma Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | ₹1.11T | 38.44 | ― | 2.10% | -0.74% | -46.77% | |
77 Outperform | ₹420.73B | 39.56 | ― | 2.29% | 5.75% | 12.41% | |
77 Outperform | ₹168.67B | 22.95 | ― | 2.03% | 10.69% | -9.09% | |
70 Outperform | ₹138.96B | 26.84 | ― | 0.29% | 19.59% | 47.58% | |
70 Outperform | ₹73.80B | 20.24 | ― | 3.84% | -5.74% | 2.30% | |
65 Neutral | ₹511.12B | 45.19 | ― | 0.65% | 17.57% | 46.53% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
IN:MARKSANS
Marksans Pharma Limited
306.65
116.72
61.46%
IN:CIPLA
Cipla Ltd
1,380.00
-117.54
-7.85%
IN:GLAND
Gland Pharma Ltd.
3,097.50
1,140.16
58.25%
IN:GLAXO
GlaxoSmithKline Pharmaceuticals Limited
2,483.55
-135.33
-5.17%
IN:PFIZER
PFIZER LIMITED
3,687.05
-1,407.11
-27.62%
IN:SANOFI
Sanofi India Limited
3,204.40
-1,441.42
-31.03%
Marksans Pharma Limited Corporate Events
Marksans Pharma Opens SEBI-Mandated Window for Re-Lodging Physical Share Transfers
Sep 17, 2026
Marksans Pharma Limited has announced the opening of a special window for shareholders to re-lodge transfer requests for physical shares purchased before April 1, 2019 that were previously rejected or not processed due to documentation deficiencie...
Marksans Pharma to Join Elara India Dialogue 2026 Investor Meet
Sep 1, 2026
Marksans Pharma Limited has scheduled participation in the Ashwamedh – Elara India Dialogue 2026, an investor and analyst meeting to be held on 2 September 2026 at the Hyatt in Santacruz East, Mumbai. The company emphasized that no unpublish...
Marksans Pharma Files Business Responsibility and Sustainability Report for FY 2025-26
Aug 4, 2026
Marksans Pharma Limited, a Mumbai-based listed pharmaceutical manufacturer, derives all its revenue from research, production and sale of generic, specialty, OTC and prescription formulations. Its portfolio includes tablets, capsules, soft gels, o...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.